Literature DB >> 2757907

The effect of vigabatrin on brain and platelet GABA-transaminase activities.

J B Bolton1, E Rimmer, J Williams, A Richens.   

Abstract

1. The inhibition profiles of GABA-transaminase (GABA-T) in rat brain and platelet have been compared following a single intraperitoneal dose of vigabatrin. The inhibition profiles exhibit similarities. The inhibition produced by the drug is dose-dependent and, in the dose range used in man, the dose-response curves are comparable. The pharmaco-dynamic effects of the drug (inhibition of central and peripheral GABA-T) remain after the drug has been eliminated from plasma. It is suggested that the measurement of rat platelet GABA-T may be used as a non-invasive assessment of the efficacy of GABA-T inhibitors in the rat CNS. 2. Human blood platelet GABA-T was significantly inhibited by the administration of a single oral dose of vigabatrin. Chronic administration also produces a significant inhibition of platelet GABA-T. As with rats, the pharmacodynamic effects on the platelet enzyme remained after the drug had been eliminated from plasma. If the situation in man is assumed to parallel that found in the rat then measurement of platelet GABA-T inhibition could prove to be a useful indicator of central inhibition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757907      PMCID: PMC1379677          DOI: 10.1111/j.1365-2125.1989.tb03459.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  GABA-transaminases of human brain and peripheral tissues--kinetic and molecular properties.

Authors:  H L White; T L Sato
Journal:  J Neurochem       Date:  1978-07       Impact factor: 5.372

3.  Enzyme-activated irreversible inhibition of rat and mouse brain 4-aminobutyric acid-alpha-ketoglutarate transaminase by 5-fluoro-4-oxo-pentanoic acid.

Authors:  B Lippert; B W Metcalf; R J Resvick
Journal:  Biochem Biophys Res Commun       Date:  1982-09-16       Impact factor: 3.575

4.  Long-term study of gamma-vinyl GABA in the treatment of epilepsy.

Authors:  S A Pedersen; P Klosterskov; L Gram; M Dam
Journal:  Acta Neurol Scand       Date:  1985-09       Impact factor: 3.209

5.  gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice.

Authors:  M J Jung; B Lippert; B W Metcalf; P Böhlen; P J Schechter
Journal:  J Neurochem       Date:  1977-11       Impact factor: 5.372

6.  Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy.

Authors:  E M Rimmer; A Richens
Journal:  Lancet       Date:  1984-01-28       Impact factor: 79.321

7.  The biochemical genetics of human gamma-aminobutyric acid transaminase.

Authors:  S Jeremiah; S Povey
Journal:  Ann Hum Genet       Date:  1981-07       Impact factor: 1.670

8.  4-aminobutyrate:2-oxoglutarate aminotransferase in blood platelets.

Authors:  H L White
Journal:  Science       Date:  1979-08-17       Impact factor: 47.728

  8 in total
  10 in total

Review 1.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

2.  Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.

Authors:  Wynne K Schiffer; Douglas Marsteller; Stephen L Dewey
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

3.  Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+ -coupled amino-acid transporter hPAT1.

Authors:  Emily L Abbot; Danielle S Grenade; David J Kennedy; Kelly M Gatfield; David T Thwaites
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

5.  Increase in brain GABA-transaminase activity after chronic ethanol treatment in rats.

Authors:  F Sherif; G Wahlström; L Oreland
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims.

Authors:  F Sherif; J Marcusson; L Oreland
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

7.  Neurobehavioral effects of vigabatrin and its ability to induce DNA damage in brain cells after acute treatment in rats.

Authors:  Karen Sousa; Natalia Decker; Thienne Rocha Pires; Débora Kuck Mausolff Papke; Vanessa Rodrigues Coelho; Pricila Pflüger; Patrícia Pereira; Jaqueline Nascimento Picada
Journal:  Psychopharmacology (Berl)       Date:  2016-09-27       Impact factor: 4.530

8.  Gamma-aminobutyrate aminotransferase activity in brains of schizophrenic patients.

Authors:  F Sherif; L Eriksson; L Oreland
Journal:  J Neural Transm Gen Sect       Date:  1992

9.  Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo.

Authors:  D L Rothman; O A Petroff; K L Behar; R H Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

10.  Subchronic treatment with antiepileptic drugs modifies pentylenetetrazol-induced seizures in mice: Its correlation with benzodiazepine receptor binding.

Authors:  Luisa Rocha
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.